| | | | | | | | |

Mesothelioma Patients See Long-Term Survival with EPP and IMRT

1819626_patient17Radical surgery and intensity modulated radiotherapy may lead to long-term survival for select pleural mesothelioma patients, but at what cost?

That is the finding, and the question, raised by cancer researchers at Japan’s Kyoto University in a recent article published in the Swedish medical journal, Acta Oncologica.

In their study of 21 pleural mesothelioma patients, intensity modulated radiotherapy (IMRT) after EPP surgery produced an overall 3-year survival rate of 37.5% – more than double the typical pleural mesothelioma survival rate of 12 to 18 months.  

IMRT in Pleural Mesothelioma Treatment

IMRT is a form of highly-targeted radiation therapy. By conforming to the shape of a mesothelioma tumor or to the margins of a tumor resection site, IMRT makes it possible to direct a high dose of radiation into cancer cells with less harm to healthy cells.

But, as the new study found, even IMRT cannot completely eliminate radiation-associated toxicities and side effects.

Side Effects of IMRT After EPP

Twenty-one mesothelioma patients were enrolled in the Japanese study. All of the patients had undergone the radical lung-removing mesothelioma surgery known as extrapleural pneumonectomy (EPP).

Although all 21 patients were supposed to receive a radiation dose of 50.4 Gy, four patients were unable to complete their course of treatment because of severe fatigue or radiation pneumonitis, a type of lung inflammation.

In all, fifteen mesothelioma patients developed acute treatment-related toxicities. In addition to pneumonitis, there were cases of serious nausea and vomiting, fatigue, and hematological problems.

Five patients developed serious radiation side-effects later including death of brain tissue (cerebral infarction), liver dysfunction, and serious deficiency of blood platelets called thrombocytopenia.

Good News for Mesothelioma Patients

Despite the side effects and complications, the study did produce some good news for people with malignant mesothelioma and their families. The median mesothelioma survival among study participants was 17.5 months after IMRT treatment and 27 months after their original surgery.

Only two patients experienced a regrowth of their tumors in the same spot after treatment, although 15 patients eventually developed metestatic mesothelioma tumors in other locations.

At the time of publication, three of the mesothelioma patients in the study had been alive for five years.

In his summary of the research, author Yukinori Matsuo reached an upbeat conclusion, but included a caveat:  

“IMRT following EPP achieved excellent local control for MPM, that might lead to the long-term survival in selected patients,” writes Matsuo. “However, treatment burden including acute and late toxicities should be considered in this treatment approach.”

Source:

Matsuo, Y, “Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma”, January 24, 2017, Acta Oncologica, Epub ahead of print,

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…